Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by
Infinium Global Research on pulmonary drugs market provides in-depth analysis
of segments and sub-segments in the global as well as regional pulmonary drugs
market. The study also highlights the impact of drivers, restraints, and macro
indicators on the global and regional pulmonary drugs market over the short
term as well as long term. The report is a comprehensive presentation of
trends, forecast and dollar values of the global pulmonary drugs market. According
to the report, the global pulmonary drugs market is projected to grow at a CAGR
of 4.3% over the forecast period of 2019-2025.
Pulmonary drugs are used in the
treatment of asthma, chronic obstructive pulmonary disease (COPD), pneumonia,
and other pulmonary disorder. Pulmonary drugs help to provide medications for
pulmonary disorders. In pulmonary drug delivery inhalation of the drug, the formulation
is through the mouth and the main purpose of this drug delivery route is
deposition of the inhaled pharmacological agent in lower airways.
Growing prevalence of chronic
obstructive pulmonary disease (COPD) drives
the growth of pulmonary drugs market. Worldwide, more than 300 million people
suffer from asthma or Chronic obstructive pulmonary disorder (COPD). Asthma is
the most common chronic disease worldwide mainly its affection is increasing in
children. Further, pulmonary drug delivery technologies are advancing very
rapidly owing to increasing adoption of the pulmonary route as an alternative
to oral and parenteral delivery methods in the pharmaceutical industry. Numbers
of new pulmonary drug candidates entering the drug development pipeline are
increasing and these advancements in pulmonary drug delivery technologies are
attracting new players and new investment. These factors boost the growth of
pulmonary drugs market. Furthermore, the rising incidence of lung diseases and
chronic obstructive pulmonary diseases owing to the increase in tobacco smoking
contribute to the growth of pulmonary drugs market. However, less awareness
regarding pulmonary drugs delivery may hamper the growth of pulmonary drugs
market.
Among the geographies, North
America dominated the pulmonary drugs market. According to the global asthma network,
asthma affects around 339 million people in all regions of the world. Among
these, 22 million persons affected by asthma in the United States. Increasing
geriatric population in the United States coupled with increasing demand for
pulmonary drugs that in turn fuel the growth of pulmonary drugs market in the
North America region. The United Nations (UN) has included asthma in all its
NCD deliberations. Growing prevalence of asthma, government initiatives for the
reduction in the treatment costs, these factors contribute to the growth of
pulmonary drugs market in the North America region. Furthermore, in Asia
Pacific, increasing expenditure on healthcare fuels the growth of pulmonary
drugs market. Ongoing initiatives and product guidance from European Medicines
Agency, International Standards Organization standards for drug delivery
devices, draft pharmacopeia monographs of the US FDA to boost the growth of
pulmonary drugs market in several regions.
The report on global pulmonary
drugs market covers segments such as drug class, application, and
distribution channel. On the basis of drug class, the sub-markets include
long-acting beta2-agonists (LABA), short-acting beta2-agonists (SABA),
anticholinergics, inhaled corticosteroids (ICS), antihistamines, vasodilators,
and other drug class. On the basis of application, the sub-markets include
pulmonary arterial hypertension, cystic fibrosis, asthma & COPD, and other
applications. On the basis of distribution channel, the sub-markets include
hospital pharmacies, retail pharmacies, drug stores, and other distribution
channel.
The report provides profiles of
the companies in the market such as Sunovion Pharmaceuticals Inc., AstraZeneca,
Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline
plc., Teva Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp,
Boehringer Ingelheim International GmbH., Actelion Pharmaceuticals Ltd, and
Others.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of pulmonary drugs market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.